ISTRUZIONE E FORMAZIONE
2015: Dottorato in Biotecnologie Mediche, Università degli Studi di Siena.
2009: Laurea Specialistica in Biotecnologie per l’ Industria e la Ricerca Scientifica, Università degli Studi di Palermo.
2007: Laurea in Biotecnologie, Università degli Studi di Palermo.
POSIZIONE E ATTIVITA’ DI RICERCA
2022-ad oggi:Borsista di Ricerca, CNR-Istituto di Biologia e Patologia Molecolari (IBPM), Roma.
Progetto di ricerca (AFM-Telethon) “Phenotypic evaluation of microtubules network as prognostic and predictive marker in response to spastin elevating approaches in Hereditary Spastic Paraplegia type 4”.
2019-2022:Assegnista di Ricerca, CNR-Istituto di Biologia e Patologia Molecolari (IBPM), Roma. Progetto di ricerca (AFM-Telethon): “The HIPK2 kinase/spastin axis in Hereditary Spastic Paraplegia.
2018-2019:Borsista di ricerca post-dottorale (EMBO Short-term fellow), Sheffield Institute for Translational Neuroscience, University of Sheffield (UK).
Progetto di ricerca: “The HIPK2 kinase/spastin axis in Hereditary Spastic Paraplegia (HSP)”.
2017-2018:Assegnista di Ricerca, CNR-Istituto di Biologia e Patologia Molecolari (IBPM), Roma.
Progetto di ricerca (Telethon): “The role of HIPK2 kinase in regulation of the spastin protein in proliferating cells and in neurons”.
2014-2016:Borsista di ricerca post-dottorale, Dipartimento di Medicina Molecolare dell’ Università “La Sapienza”, Roma.
Progetto di ricerca (AIRC): “Role of the DNA damage response in hedgehog-MYCN dependent proliferation of cerebellar stem cells and granule precursor cells”.
2010-2014:Dottoranda, Dipartimento di Medicina Molecolare dell’ Università di Roma “La Sapienza”, Roma.
Progetto di dottorato: “The MRN complex controls MYCN-dependent replication stress and is a potential therapeutic target for MYCN-amplified neuroblastoma”.
2009-2010:Tirocinante post-laurea, CNR-Istituto di Biomedicina e Immunologia Molecolare (IBIM), Palermo.
Progetto di ricerca: “The effects of the novel NF-?B inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in combination with the selective COX-2 inhibitor celecoxib, in human hepatoma cells”.
PREMI DI RICERCA
2021:A.I.Vi.P.S ETS premio di ricerca “Microtubule cytoskeleton organization as biomarker to develop new therapeutic perspectives for Hereditary Spastic Paraplegia type 4 (HSP-SPG4)”
2021:AFM-Telethon Postdoctoral fellowship “Phenotypic evaluation of microtubules network as prognostic and predictive marker in response to spastin elevating approaches in Hereditary Spastic Paraplegia type 4” (rif N°23786).
2021:Adolf-Struempell-Prize per il manoscritto dal titolo Sardina et al., LSA 2020; doi: 10.26508/lsa.202000799.
PUBBLICAZIONI
1-Sardina F (corresponding author), Valente D, Fattorini G, Cioffi E, Zanna GD, Tessa A, Trisciuoglio D, Soddu S, Santorelli FM, Casali C, Rinaldo C. New cellular imaging-based method to distinguish the SPG4 subtype of hereditary spastic paraplegia. Eur J Neurol. 2023 Jun;30(6):1734-1744. doi: 10.1111/ene.15756.
2-Sardina F, Conte A, Paladino S, Pierantoni GM, Rinaldo C. HIPK2 in the physiology of nervous system and its implications in neurological disorders. Biochim Biophys Acta Mol Cell Res. 2023 Jun;1870(5):119465. doi: 10.1016/j.bbamcr.2023.119465. Epub 2023 Mar 20. PMID: 36935052; PMCID: PMC10236203.
3-Sardina F (co-corresponding author), Pisciottani A, Ferrara M, Valente D, Casella M, Crescenzi M, Peschiaroli A, Casali C, Soddu S, Grierson AJ, Rinaldo C. Spastin recovery in hereditary spastic paraplegia by preventing neddylation-dependent degradation. Life Sci Alliance. 2020 Oct 26;3(12):e202000799. doi: 10.26508/lsa.202000799.
4-Sardina F, Monteonofrio L, Ferrara M, Magi F, Soddu S, Rinaldo C. HIPK2 Is Required for Midbody Remnant Removal Through Autophagy-Mediated Degradation.Front Cell Dev Biol. 2020 Sep 15;8:572094. doi: 10.3389/fcell.2020.572094.
5-Petroni M, Sahùn Roncero M, Ramponi V, Fabretti F, Nicolis Di Robilant V, Moretti M, Alfano V, Corsi A, De Panfilis S, Giubettini M, Di Giulio S, Capalbo C, Belardinilli F, Coppa A, Sardina F, Colicchia V, Pedretti F, Infante P, Cardinali B, Tessitore A, Canettieri G, De Smaele E, Giannini G. SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors. Sci Rep. 2019 Dec 23;9(1):19623. doi: 10.1038/s41598-019-56057-y.
6-Pisciottani A, Biancolillo L, Ferrara M, Valente D, Sardina F, Monteonofrio L, Camerini S, Crescenzi M, Soddu S, Rinaldo C. HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission. Cells. 2019 Jul 5;8(7):684. doi: 10.3390/cells8070684.
7-Petroni M, Sardina F (co-first author), Infante P, Bartolazzi A, Locatelli E, Fabretti F, Di Giulio S, Capalbo C, Cardinali B, Coppa A, Tessitore A, Colicchia V, Sahùn Roncero M, Belardinilli F, Di Marcotullio L, Soddu S, Comes Franchini M, Petricci E, Gulino A, Giannini G. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.Cell Death Dis. 2018 Aug 30;9(9):895. doi: 10.1038/s41419-018-0924-z.
8-Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.Oncogene. 2017 Aug 17;36(33):4682-4691. doi: 10.1038/onc.2017.40.
9-Petroni M, Sardina F, Heil C, Sahún-Roncero M, Colicchia V, Veschi V, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress.Cell Death Differ. 2016 Feb;23(2):197- 206. doi: 10.1038/cdd.2015.81.
10-Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, Lampiasi N, Giannitrapani L, McCubrey JA, Montalto G. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS. 2011 Jun;15(6):383-92. doi: 10.1089/omi.2010.0092.
2015: Dottorato in Biotecnologie Mediche, Università degli Studi di Siena.
2009: Laurea Specialistica in Biotecnologie per l’ Industria e la Ricerca Scientifica, Università degli Studi di Palermo.
2007: Laurea in Biotecnologie, Università degli Studi di Palermo.
POSIZIONE E ATTIVITA’ DI RICERCA
2022-ad oggi:Borsista di Ricerca, CNR-Istituto di Biologia e Patologia Molecolari (IBPM), Roma.
Progetto di ricerca (AFM-Telethon) “Phenotypic evaluation of microtubules network as prognostic and predictive marker in response to spastin elevating approaches in Hereditary Spastic Paraplegia type 4”.
2019-2022:Assegnista di Ricerca, CNR-Istituto di Biologia e Patologia Molecolari (IBPM), Roma. Progetto di ricerca (AFM-Telethon): “The HIPK2 kinase/spastin axis in Hereditary Spastic Paraplegia.
2018-2019:Borsista di ricerca post-dottorale (EMBO Short-term fellow), Sheffield Institute for Translational Neuroscience, University of Sheffield (UK).
Progetto di ricerca: “The HIPK2 kinase/spastin axis in Hereditary Spastic Paraplegia (HSP)”.
2017-2018:Assegnista di Ricerca, CNR-Istituto di Biologia e Patologia Molecolari (IBPM), Roma.
Progetto di ricerca (Telethon): “The role of HIPK2 kinase in regulation of the spastin protein in proliferating cells and in neurons”.
2014-2016:Borsista di ricerca post-dottorale, Dipartimento di Medicina Molecolare dell’ Università “La Sapienza”, Roma.
Progetto di ricerca (AIRC): “Role of the DNA damage response in hedgehog-MYCN dependent proliferation of cerebellar stem cells and granule precursor cells”.
2010-2014:Dottoranda, Dipartimento di Medicina Molecolare dell’ Università di Roma “La Sapienza”, Roma.
Progetto di dottorato: “The MRN complex controls MYCN-dependent replication stress and is a potential therapeutic target for MYCN-amplified neuroblastoma”.
2009-2010:Tirocinante post-laurea, CNR-Istituto di Biomedicina e Immunologia Molecolare (IBIM), Palermo.
Progetto di ricerca: “The effects of the novel NF-?B inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in combination with the selective COX-2 inhibitor celecoxib, in human hepatoma cells”.
PREMI DI RICERCA
2021:A.I.Vi.P.S ETS premio di ricerca “Microtubule cytoskeleton organization as biomarker to develop new therapeutic perspectives for Hereditary Spastic Paraplegia type 4 (HSP-SPG4)”
2021:AFM-Telethon Postdoctoral fellowship “Phenotypic evaluation of microtubules network as prognostic and predictive marker in response to spastin elevating approaches in Hereditary Spastic Paraplegia type 4” (rif N°23786).
2021:Adolf-Struempell-Prize per il manoscritto dal titolo Sardina et al., LSA 2020; doi: 10.26508/lsa.202000799.
PUBBLICAZIONI
1-Sardina F (corresponding author), Valente D, Fattorini G, Cioffi E, Zanna GD, Tessa A, Trisciuoglio D, Soddu S, Santorelli FM, Casali C, Rinaldo C. New cellular imaging-based method to distinguish the SPG4 subtype of hereditary spastic paraplegia. Eur J Neurol. 2023 Jun;30(6):1734-1744. doi: 10.1111/ene.15756.
2-Sardina F, Conte A, Paladino S, Pierantoni GM, Rinaldo C. HIPK2 in the physiology of nervous system and its implications in neurological disorders. Biochim Biophys Acta Mol Cell Res. 2023 Jun;1870(5):119465. doi: 10.1016/j.bbamcr.2023.119465. Epub 2023 Mar 20. PMID: 36935052; PMCID: PMC10236203.
3-Sardina F (co-corresponding author), Pisciottani A, Ferrara M, Valente D, Casella M, Crescenzi M, Peschiaroli A, Casali C, Soddu S, Grierson AJ, Rinaldo C. Spastin recovery in hereditary spastic paraplegia by preventing neddylation-dependent degradation. Life Sci Alliance. 2020 Oct 26;3(12):e202000799. doi: 10.26508/lsa.202000799.
4-Sardina F, Monteonofrio L, Ferrara M, Magi F, Soddu S, Rinaldo C. HIPK2 Is Required for Midbody Remnant Removal Through Autophagy-Mediated Degradation.Front Cell Dev Biol. 2020 Sep 15;8:572094. doi: 10.3389/fcell.2020.572094.
5-Petroni M, Sahùn Roncero M, Ramponi V, Fabretti F, Nicolis Di Robilant V, Moretti M, Alfano V, Corsi A, De Panfilis S, Giubettini M, Di Giulio S, Capalbo C, Belardinilli F, Coppa A, Sardina F, Colicchia V, Pedretti F, Infante P, Cardinali B, Tessitore A, Canettieri G, De Smaele E, Giannini G. SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors. Sci Rep. 2019 Dec 23;9(1):19623. doi: 10.1038/s41598-019-56057-y.
6-Pisciottani A, Biancolillo L, Ferrara M, Valente D, Sardina F, Monteonofrio L, Camerini S, Crescenzi M, Soddu S, Rinaldo C. HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission. Cells. 2019 Jul 5;8(7):684. doi: 10.3390/cells8070684.
7-Petroni M, Sardina F (co-first author), Infante P, Bartolazzi A, Locatelli E, Fabretti F, Di Giulio S, Capalbo C, Cardinali B, Coppa A, Tessitore A, Colicchia V, Sahùn Roncero M, Belardinilli F, Di Marcotullio L, Soddu S, Comes Franchini M, Petricci E, Gulino A, Giannini G. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.Cell Death Dis. 2018 Aug 30;9(9):895. doi: 10.1038/s41419-018-0924-z.
8-Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.Oncogene. 2017 Aug 17;36(33):4682-4691. doi: 10.1038/onc.2017.40.
9-Petroni M, Sardina F, Heil C, Sahún-Roncero M, Colicchia V, Veschi V, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress.Cell Death Differ. 2016 Feb;23(2):197- 206. doi: 10.1038/cdd.2015.81.
10-Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, Lampiasi N, Giannitrapani L, McCubrey JA, Montalto G. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS. 2011 Jun;15(6):383-92. doi: 10.1089/omi.2010.0092.